Table 1 Clinical characteristics of study cohorts.
From: Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer
Characteristic | ||
|---|---|---|
Localized prostate cancer cohort | n (%) | P a |
Patients, n | 458 | |
Age at diagnosis | 0.303 | |
Median, y (IQR) | 66 (61–70) | |
≤65 | 211 (46.1) | |
>65 | 247 (53.9) | |
PSA at diagnosis | <0.001 | |
Median, ng/mL (IQR) | 11.1 (7.1–17.5) | |
≤10 | 197 (44.9) | |
>10 | 242 (55.1) | |
Pathologic Gleason score, n (%) | <0.001 | |
≤6 | 160 (35.3) | |
>6 | 293 (64.7) | |
Pathologic stage, n (%) | <0.001 | |
T1/T2 | 303 (67.2) | |
T3/T4/N1 | 148 (32.8) | |
BCR | 184 (40.2) | |
Median follow-up timeb, mo (95% CI) | 54 (50–58) | |
Advanced prostate cancer cohort | n (%) | P c |
Patients, n | 504 | |
Age at diagnosis | 0.016 | |
Median, y (IQR) | 73 (66–79) | |
≤72 | 250 (49.6) | |
>72 | 254 (50.4) | |
PSA at ADT initiation | 0.022 | |
Median, ng/mL (IQR) | 33.8 (9.3–133.3) | |
≤34 | 253 (51.6) | |
>34 | 237 (48.4) | |
Biopsy Gleason score at diagnosis, n (%) | <0.001 | |
≤7 | 312 (63.4) | |
>7 | 180 (36.6) | |
Clinical stage at diagnosis, n (%) | <0.001 | |
M0 | 308 (61.4) | |
M1 | 194 (38.6) | |
PSA nadir | <0.001 | |
Median, ng/mL (IQR) | 0.14 (0.01–1.06) | |
<0.2 | 275 (54.8) | |
≥0.2 | 227 (45.2) | |
Time to PSA nadir | <0.001 | |
Median, mo (IQR) | 10 (5–20) | |
<10 | 236 (47.0) | |
≥10 | 266 (53.0) | |
Treatment modality | 0.002 | |
ADT as primary treatment | 254 (50.5) | |
ADT for post RP PSA failure | 73 (14.5) | |
ADT for post RT PSA failure | 12 (2.4) | |
Neoadjuvant/adjuvant ADT with RT | 122 (24.3) | |
Others | 42 (8.3) | |
Disease progression | 457 (90.7) | |
Median follow-up timeb, mo (95% CI) | 87 (79–95) | |
